| Home > Publications database > α‐Synuclein Aggregate‐Disassembling Compounds Prolong Survival in a Mouse Model of Parkinson's Disease |
| Journal Article | FZJ-2026-04734 |
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
2026
Wiley
Hoboken, NJ
This record in other databases:
Please use a persistent id in citations: doi:10.1002/agt2.70439
Abstract: Pathological aggregation of α-synuclein drives neuronal loss in Parkinson’s disease. We therefore tested two optimized all- d - peptides, SVD-17 and SVD-1a, alongside the prototype SVD-1. Surface plasmon resonance revealed that SVD-17 binds monomeric α-synuclein with a nanomolar KD of 1.09 nM. In vitro, SVD-17 and SVD-1a dismantled existing fibrils, rendering 50 % of them seeding-incompetent at 1.4 μM and 5.1 μM, respectively, and suppressed seeded aggregation in HEK293 α-synuclein biosensor cells with an IC50 of 1.6 μM. Hemizygous TgM83+ / − mice received continuous subcutaneous infusion of each peptide for 3 months following intraperitoneal fibril seeding and were then monitored for neurological decline. Treatment with SVD-17 or SVD-1a extended median survival by 14% and 15%, whereas SVD-1 provided no significant benefit. Collectively, SVD-17 and SVD-1a bind α-synuclein with high affinity, disaggregate pathogenic assemblies, block further polymerization, and improve outcomes in a stringent in vivo model, underscoring their potential as disease-modifying therapeutics for Parkinson’s disease and other synucleinopathies.
|
The record appears in these collections: |